Investigational Drug Information for AV-101
✉ Email this page to a colleague
What is the development status for investigational drug AV-101?
AV-101 is an investigational drug.
There have been 8 clinical trials for AV-101.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2021.
The most common disease conditions in clinical trials are Pulmonary Arterial Hypertension, Depressive Disorder, and Hypertension. The leading clinical trial sponsors are VistaGen Therapeutics, Inc., Aerovate Therapeutics, and Parexel.
There are twenty-four US patents protecting this investigational drug and two hundred and eighty-nine international patents.
Summary for AV-101
| US Patents | 24 |
| International Patents | 289 |
| US Patent Applications | 84 |
| WIPO Patent Applications | 50 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 2 (2021-11-01) |
| Vendors | 21 |
Recent Clinical Trials for AV-101
| Title | Sponsor | Phase |
|---|---|---|
| Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) | Aerovate Therapeutics | Phase 2/Phase 3 |
| AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia | VistaGen Therapeutics, Inc. | Phase 2 |
| AV-101 Alone and in Combination With Probenecid in Healthy Subjects | Parexel | Phase 1 |
Clinical Trial Summary for AV-101
Top disease conditions for AV-101
Top clinical trial sponsors for AV-101
US Patents for AV-101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AV-101 | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| AV-101 | ⤷ Sign Up | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | ⤷ Sign Up |
| AV-101 | ⤷ Sign Up | Methods for the synthesis of chiral kynurenine compounds | VISTAGEN THERAPEUTICS, INC. (South San Francisco, CA) | ⤷ Sign Up |
| AV-101 | ⤷ Sign Up | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | ⤷ Sign Up |
| AV-101 | ⤷ Sign Up | Composition and method for treatment of depression and psychosis in humans | GLYTECH, LLC (Ft. Lee, NJ) | ⤷ Sign Up |
| AV-101 | ⤷ Sign Up | Dosage forms and therapeutic uses of L-4-chlorokynurenine | VISTAGEN THERAPEUTICS, INC. (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AV-101
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AV-101 | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| AV-101 | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| AV-101 | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| AV-101 | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| AV-101 | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| AV-101 | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
